Format

Send to

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6.

Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Author information

1
Peptide Biochemistry Res. Group of Hung. Acad. Sci. and Cooperative Research Centre, Semmelweis University, Rippl-Rónai u. 37., Budapest 1062, Hungary.

Abstract

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined LogP and LogS values.

PMID:
15925511
DOI:
10.1016/j.bmcl.2005.04.064
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center